The combination group included those who added a newer generation GLP-1RA (i.e., exenatide once weekly [OW], dulaglutide, semaglutide OW T2D, or oral semaglutide) or dual GLP-1/GIP agonist (tirzepatide T2D) to their SGLT2i (i.e., canagliflozin, dapagliflozin, empagliflozin, ertugliflozin, or bexagliflozin) treatment, with persistent use of a GLP-1RA and SGLT2i for 180 days each and an overlap 120 days, where the gap after exhaustion of days supply was required to be 30 days
The "Ozempic Face" and Rapid-Loss Phenotype Rapid weight loss, whether from GLP-1 therapy, very-low-calorie diets, or bariatric surgery, can produce similar visible changes: reduced facial adipose tissue, changes in skin laxity, and altered body contour
Referencias: Buford, T
Dweck cautions that research on GLP-1 dosing for women in perimenopause is slim and ongoing
Thymosin Beta-4 functions as the principal regulator of monomeric actin availability in most cell types, sequestering approximately 40-50% of the total G-actin pool
Further damage to the SLIL can cause dynamic instability which can remain concealed on a standard radiograph
